Photodynamic Therapy News and Research

RSS

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.

15 Apr 2011

Targeted photodynamic therapy eradicates some models of cancer

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer.

12 Apr 2011

Non-laser light treatments may help treat common skin conditions

While dermatologists have used lasers successfully for years to treat common skin conditions such as acne, rosacea and aging skin, it now appears that even non-laser lights may provide some of the same benefits.

16 Mar 2011

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.

16 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Endoscopic removal of pre-cancerous cells in patients with confirmed, high-risk Barrett's esophagus is recommended rather than surveillance, according to a new "Medical Position Statement on the Management of Barrett's Esophagus," published by the American Gastroenterological Association (AGA) Institute. The medical position statement was published in Gastroenterology, the official journal of the AGA Institute.

1 Mar 2011

Photodynamic therapy could be useful in eradicating tumor-associated lymphatic vessels

Tumor cells have several routes that enable them to move from the primary tumor to distant tissues, a process called metastasis. It is metastasis of the primary tumor that kills most cancer patients. One of the least studied routes of metastasis is the lymphatic system. Many tumors produce factors that promote the formation of new lymphatic vessels (lymphangiogenesis).

10 Feb 2011

Anti-cancer drug tied to golden missiles

Researchers at Case Western Reserve University have developed a little bomb that promises a big bang for cancer patients.

5 Feb 2011

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

Photocure, a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.

4 Feb 2011

More needs to be done globally to fight cancer

WHILE cancer statistics for the last 10 years make encouraging reading, more needs to be done globally to fight the killer disease.

4 Feb 2011

Light therapy can help preserve vocal cord function for patients with early stage laryngeal cancer: Study

Light, or photodynamic, therapy can help preserve the voice and vocal cord function for patients with early stage laryngeal (voice box) cancer, according to a study from Henry Ford Hospital in Detroit.

29 Jan 2011

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Roswell Park Cancer Institute (RPCI) on December 13, 2010, announced the formation of Photolitec, LLC, a new life-sciences company at RPCI that will develop photosensitizing compounds used in photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI by scientist Thomas J. Dougherty, Chief Emeritus of the Institute's Photodynamic Therapy Center.

15 Dec 2010

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

QLT Inc. today announced that its wholly-owned U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"), and Quantel Medical and its distributor, Quantel USA, Inc., have entered into a co-promotion agreement for the sale of Activis PDT Lasers used to activate Visudyne® during photodynamic therapy of primarily classic lesions in wet age-related macular degeneration (AMD). The lasers are manufactured by Quantel Medical and sold by Quantel USA, Inc. and will be promoted by both Quantel USA, Inc. and QOI's sales force to the retina community in the United States.

29 Nov 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

New LED device may help advance photodynamic therapy for skin cancer

Can skin cancer be treated with light? Scientists at the University of California, Irvine (UC Irvine), believe so. They're exploring new ways to image cancerous lesions using LEDs that might advance a technique for treating cancer called photodynamic therapy (PDT) -- work that they will describe at the Optical Society's (OSA) 94th annual meeting, Frontiers in Optics (FiO) 2010 at the Rochester Riverside Convention Center in Rochester, N.Y., from Oct. 24-28.

19 Oct 2010

Study finds no link between AMD treatments and increase in cardiovascular complication

Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

FDA declines to grant Levulan PDT Orphan Designation: DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.

7 Aug 2010

DUSA Pharmaceuticals total product revenues for second-quarter 2010 increase 25% to $8.7 million

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2010.

3 Aug 2010

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

28 Jul 2010